Context: Brain-derived neurotrophic factor (BDNF) plays a pivotal role in the pathophysiology of suicidal behavior and BDNF levels are decreased in the brain and plasma of suicide subjects. So far, the mechanisms leading to downregulation of BDNF expression are poorly understood.
B
RAIN-DERIVED NEUROTROPHIC factor (BDNF), a member of the neurotrophin family, plays a key role in the development and survival of neurons in the central nervous system. 1 BDNF binds to a specific tyrosine kinase receptor (tropomyosin-related kinase B receptor [trkB] ) and regulates many functions related to neuron development such as neurite outgrowth, synthesis of differentiating factors, and morphological plasticity. 1 In adulthood, BDNF is involved in neural homeostasis and in processes related to neuronal plasticity and connectivity, including learning and memory, 2,3 drug addiction, 4 response to social stress, aggressiveness, and anxietylike behaviors. 5, 6 Alteration of BDNF expression in specific neurons may reduce neural plasticity, therefore impairing the ability to respond to stressors, and contributes to different neurodegenerative and neuropsychiatric disorders including depression and bipolar disorder. 7 Singlenucleotide polymorphisms of the BDNF gene have also been associated, although with conflicting results, with different psychiatric conditions, including schizophrenia and suicidal behavior. [8] [9] [10] Recent studies demonstrate that BDNF levels are decreased in the brain (prefrontal cortex and hippocampus) of suicide victims, 11, 12 suggesting that BDNF plays a role in the pathophysiological aspects of suicidal behavior. The expression of the hu-man BDNF gene is controlled by a complex regulatory region, well conserved in mouse and rat, 13 that includes at least 9 promoters each driving transcription of BDNF messenger RNA (mRNA) transcripts containing 1 of the nine 5Ј noncoding exons. 14 BDNF promoter IV has been shown to be highly regulated during development, and epigenetic mechanisms play a key role in such regulation. [15] [16] [17] The DNA methylation state of CpG sites within mouse promoter/exon IV is correlated with the expression of BDNF in the developing mouse forebrain. 15 Very interestingly, the neuronal activity-dependent activation of the BDNF gene is mediated by decreased CpG methylation of BDNF promoter IV and the release of a chromatin repressor complex containing MeCP2 methylbinding protein. 18, 19 Moreover, promoter IV is the major target of chromatin changes associated with alteration of BDNF expression in mouse models of neuropsychiatric disorders. 6, 20 However, to our knowledge, no data on the methylation state of the BDNF gene, either in human mental illness or in suicide victims, have been reported so far.
In the present study, we quantitatively analyzed the DNA methylation degree of 4 CpG sites within the human BDNF promoter/exon IV in the postmortem brain (Wernicke area) of 44 suicide completers and 33 control subjects. We also determined the global DNA methylation state in the same samples and the BDNF mRNA levels in some samples that displayed a different BDNF methylation degree. Our results showed that DNA methylation levels at BDNF promoter IV were increased in suicide victims compared with normal control subjects, irrespective of global DNA methylation degree, and that the amount of BDNF transcript IV was lower in samples displaying a higher BDNF promoter IV methylation.
METHODS

STUDY SUBJECTS
The study was performed on postmortem samples of brain tissue extracted from the Wernicke area obtained from 44 suicide completers and 33 nonsuicide control subjects. Most of the autoptic samples were collected within 12 to 26 hours of the subject's death (postmortem interval information is reported in the eTable, http://www.archgenpsychiatry.com), in the course of autopsy at the Institute of Forensic Medicine, University of Ljubljana, between 1999 and 2005, and stored at −80°C in the care of the Biological Bank of the Institut za Varovanje Zdravja, Ljubljana, Slovenia. This study was performed according to the ethical requirements of the institution. All studied subjects were of white ethnicity and all were right handed. Data on subjects' sex, age, drug history, and cause of death were gathered from the subjects' records. Data on psychiatric diagnoses were obtained from the physician's note for autopsy, and in the cases in which a coroner's inquest was done in the presence of relatives, their testimony was taken into consideration. A detailed description of the subjects analyzed in this study is reported in the eTable.
pH MEASUREMENT AND DRUG ANALYSIS
Blood was taken from the subjects to perform general toxicological screening using gas chromatography-mass spectro-metry. The analysis of pH of the homogenate was performed using the automated analyzer 865 (Bayer Leverkusen, Germany, now Siemens, Malvern, Pennsylvania). A 50-to 100-mg sample of liquid nitrogen-pulverized tissue was mixed with distilled deionized water in a 10% (weight to volume ratio) solution. To confirm blood data, we also performed drug analysis on homogenates, using the REMEDI column-switching LC instrument (Bio-Rad Laboratories, Hercules, California), which detects about 700 drugs or metabolites, including most illicit substances and drugs of abuse or their direct metabolites. 21
DNA AND RNA EXTRACTION FROM TISSUES
DNA and RNA were extracted, from each sample, from a portion of liquid nitrogen-pulverized tissue. DNA was prepared using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), following the instruction manual. Total RNA was extracted from tissues using TRI Reagent solution (Invitrogen, Carlsbad, California), according to the manufacturer's instructions. The integrity of the RNA was assessed by denaturing agarose gel electrophoresis (eFigure). RNA quality and quantity assessment was performed by an ND-1000 NanoDrop spectrophotometer (NanoDrop Products, Wilmington, Delaware). All samples showed a quality ratio (260: 280-260:230) between 1.8 and 2.2, which is considered an optimal range. 22 Negative controls were obtained by performing polymerase chain reaction (PCR) on samples that were not reverse transcribed but otherwise identically processed.
BISULFITE TREATMENT
Sodium bisulfite conversion of genomic DNA (2 µg) was obtained using Epitect Bisulphite kit (Qiagen), following the manufacturer's instructions. Amplicons used for the different methylation analyses were obtained from appropriate amounts of bisulfite-treated genomic DNA.
DNA METHYLATION ANALYSIS
Pyrosequencing
Pyrosequencing technology 23 was used for DNA methylation quantitative analysis of the BDNF gene and was performed using the PSQ 96MA instrument (Biotage AB, Uppsala, Sweden), following the manufacturer's protocol. The reactions were assayed on the PSQ 96MA using the single-nucleotide polymorphism analysis software. Global DNA methylation analysis was performed using the PyroMark LINE-1 assay kit (Biotage AB), according to the manufacturer's instructions. Long interspersed nucleotide elements (LINE-1) represent about 15% of the human genome; thus, quantitative DNA methylation analysis of LINE-1 may be considered a surrogate analysis of global DNA methylation. 24 Primer sequences and detailed protocol for BDNF and global methylation analysis can be found in the supplementary Methods section.
Bisulfite Genomic Sequencing (Cloning Technology)
Two microliters of each sample were used as a template in PCR reactions using the following primers: BDNF FW2 5Ј-gggggaggattaaTtgagTTagttTtg-3Ј (position from nucleotides −358 to −332) and BDNF RV2 5Ј-cccatcaacRaaaaactccatttaatctc-3Ј (from nucleotides ϩ59 to ϩ87). Amplifications and the cloning procedure were performed as previously described. 25 At least 20 independent clones were sequenced to determine the methylation pattern of individual molecules.
MassARRAY Platform
The MassARRAY platform (Sequenom, San Diego, California) uses matrix-assisted laser desorption ionization-time-offlight (MALDI-TOF) mass spectrometry in combination with RNA base-specific cleavage (MassCLEAVE; Sequenom). A detectable pattern was then analyzed for methylation status. The MassCLEAVE biochemistry was performed as previously described. 26 Mass spectra were acquired by using MassARRAY Compact MALDI-TOF mass spectrometry (Sequenom) and the spectra methylation ratios were generated by EpiTYPER software (version 1.0; Sequenom). Further technical information and primer sequences can be found in the supplementary Methods section. Presence of a CpG island in the genomic region analyzed was assessed by using CGplot software (http://www .ebi.ac.uk/emboss/cpgplot/).
REAL-TIME REVERSE TRANSCRIPTION-PCR
One microgram of total RNA of each sample was reverse transcribed with the QuantiTect Reverse Transcription kit (Qiagen) using an optimized blend of oligo-dT and random primers, according to the manufacturer's instructions. Primer sequences and detailed protocol for BDNF and the internal con-trol genes' quantitative mRNA analysis can be found in the supplementary Methods section. The strategy used for the normalization of quantitative real-time reverse transcription-PCR (RT-PCR) data was geometric averaging of multiple internal control genes according to the Vandesompele et al 27 method. We evaluated 4 housekeeping genes (GAPDH, HPRT I, UBC, and RP II) that represent accurate controls for mRNA expression analysis of postmortem brain samples. [27] [28] [29] For each housekeeping gene, we measured the gene stability and ranked it using the geNorm algorithm. 27 Stepwise exclusion of the gene with the highest gene stability value allowed ranking of the tested genes according to their expression stability. We applied to each sample the delta Ct formula for transforming Ct values to relative quantities (Q=E (minCt−sampleCt) ), as described elsewhere. 27 We calculated the normalization factor based on the geometric mean of quantity obtained by the transformation of Ct data. A sample (sample ID 920/04), arbitrarily chosen among control subjects' RNA, was used as a reference sample. Amplification over 32 cycles was considered out of linear range. 30 
STATISTICAL ANALYSES
We performed statistical analyses with the SPSS software package (version 13.0; SPSS, Chicago, Illinois). We used 1-way analysis of variance to compare methylation levels between sample groups. P values Ͻ.05 were considered statistically significant. The Mann-Whitney U test was used to compare nongaussian distribution. Analysis of covariance was used to assess the possible influence of sex and age.
RESULTS
METHYLATION ANALYSIS OF BDNF PROMOTER IV IN THE WERNICKE AREA OF SUICIDE VICTIMS AND NORMAL CONTROL SUBJECTS
To investigate a possible correlation between the DNA methylation state of the BDNF gene and suicidal behavior, we analyzed genomic DNA samples derived from postmortem brain samples extracted from the Wernicke area of 44 suicide completers (21 men and 23 women; age range, 15-79 years) and 33 nonsuicide controls (16 men and 17 women; age range, 13-76 years). A detailed description of the subjects analyzed in this study, including psychiatric diagnoses, medication, and toxicological findings, is reported in the eTable.
We chose to analyze the methylation status of 4 CpG sites (ϩ10, ϩ16, ϩ25, and ϩ28) located downstream the transcription initiation site of promoter IV of the BDNF gene ( Figure 1A) . These sites are embedded in a small CpG island (located from −99 to ϩ101) spanning the transcriptional start site (TSS). A quantitative methylation analysis was performed using the pyrosequencing technology to assess the precise degree of methylation of each CpG site. A representative pyrogram is shown in Figure 1B . Full raw data, indicating the methylation degree of each CpG site in each sample, are reported in the Table. The analysis was repeated 3 times and each value did not differ significantly (±0.7%). The mean methylation degree of the 4 CpG sites in each subject is also reported in the Table and graphically shown in Figure 2 . Overall, the results showed that the mean methylation degree of the 4 CpG sites was always less than 12.9% in the 33 nonsuicide control subjects, while in 13 of 44 sui- cide victims (30%), the mean methylation degree ranged between 13.1% and 34.2% ( Figure 2 and the Table) . To establish whether the observed differences in the mean methylation degree between suicide and nonsuicide subjects were statistically significant, we performed 1-way analysis of variance. As shown in Figure 3A , significant differences were clearly discernible in the mean methylation status of the region analyzed between cases and controls (1-way analysis of variance, F = 13.7; P =.001). By the same method, we analyzed the relationship between the methylation degree of each of the 4 CpG sites and suicidal behavior. Statistically significant differences between cases and controls were found for the CpG sites ϩ10 and ϩ25 ( Figure 3B ). A similar, but not statistically significant, trend to hypermethylation was found for the other 2 CpG sites tested (ϩ16 and ϩ28). We also analyzed the data by a nonparametric test (Mann-Whitney U test), obtaining similar results. Statistically significant differences between cases and controls were found for the mean methylation of the region (Mann-Whitney U test, P=.001) and for CpG sites ϩ10 and ϩ25 (P=.002 and .001, respectively). No effect of sex or age was found by analysis of covariance (data not shown).
Next, because the global DNA methylation state of specific brain areas could vary among individuals, we addressed whether an increased methylation degree of BDNF promoter/exon IV in suicide victims was associated with higher methylation levels throughout the genome or whether it was a specific feature of the BDNF gene. We studied global methylation in all suicide and control samples by quantitatively analyzing the methylation of LINE-1, using pyrosequencing. A representative pyro- gram is shown in Figure 1B , bottom panel. Results, summarized in the Table, indicate that global methylation ranged between 81% and 90% among individuals. However, no correlation was found between global methylation and BDNF promoter IV methylation degree (data not shown). Moreover, global methylation levels were not associated with suicidality, sex, or age (data not shown). Finally, we verified whether psychopathological conditions or past or current use of specific medications could influence the BDNF gene methylation state. Drug history indicated that no subject used psychoactive substances during life other than those detected by toxicological screens and reported in the eTable. We found no significant correlation between any of these variables and the methylation degree at the BDNF promoter (Mann-Whitney U test, P= .30 and .14, respectively).
Overall, our results show that BDNF promoter/exon IV is hypermethylated in the postmortem brain Wernicke area of suicide subjects compared with normal control subjects irrespective of global methylation levels, suggesting that a gene-specific increase in DNA methylation could cause or contribute to downregulation of BDNF expression in suicide subjects.
EXTENDED METHYLATION ANALYSIS BY MOLECULAR CLONING AND MassARRAY
To extend the methylation analysis to a wider genomic region and to both upper and lower strands, we performed 2 additional independent quantitative methylation analyses, bisulfite genomic sequencing (molecular cloning technique) and a mass spectrometry-based methylation analysis (MassARRAY). These analyses were performed in a subgroup of subjects (n=24) including 13 suicide completers and 11 control subjects of different ages and sex. We analyzed by bisulfite genomic sequencing the genomic region from −203 to ϩ58 (upper strand) encompassing the TSS of the BDNF gene and including 16 CpG sites (Figure 4) . The results showed that the analyzed BDNF gene region was mainly unmethylated or low methylated and that the differentially methylated sites were essentially those lying in the proximity of the TSS. The results confirmed that sites ϩ10, ϩ16, ϩ25, and ϩ28 were differentially methylated between suicide and control subjects, showing methylation values comparable with those obtained by pyrosequencing analysis. In addition, to confirm the pyrosequencing data, (Figure 5 ). This analysis showed that also in this wider genomic region most of the CpG sites were unmethylated or low methylated in both suicide and control subjects and that, on the upper strand, sites ϩ10, ϩ16, ϩ25, and ϩ28 remained differentially methylated. Differences in the methylation degree of these same sites detected on the lower strand were slighter but a higher methylation level was detected at some of these CpG sites where the correspondent sites on the upper strand were hypermethylated. Finally, frequent hypermethylation of −93 on the upper strand site was confirmed in these experiments. Slight differences in the methylation degree at some CpG sites observed in the analysis by the different technical approaches were possibly due to the different sensitivity of the methods.
RELATIONSHIP BETWEEN BDNF EXPRESSION AND BDNF PROMOTER IV METHYLATION DEGREE
To assess whether hypermethylation of BDNF promoter IV (CpG sites ϩ10, ϩ16, ϩ25, and ϩ28) was associated with decreased gene expression, we analyzed by realtime RT-PCR the BDNF mRNA (transcript IV) levels in the same subgroup of subjects. We analyzed 13 samples from the suicide victims and 11 from control subjects, in particular, 10 samples (4 from the suicide group and 6 from the control group) with a low level of methylation at BDNF promoter IV, 9 samples (4 from the suicide group and 5 from the control group) showing intermediate methylation levels, and 5 samples from suicide subjects with the highest methylation degree (Figure 6 ). For this quantitative RT-PCR assay, we used specific prim- ers for the analysis of BDNF mRNA transcript originating from promoter IV. The analyzed samples showing a high-methylated BDNF promoter IV expressed lower levels of BDNF mRNA as compared with the low-and medium-methylated samples, being the mildly methylated samples in the midrange (Figure 6 ). Taken together, our data indicate that a highermethylated BDNF promoter IV in the Wernicke area of the brain correlates with suicidal behavior and suggests that increased DNA methylation levels of BDNF promoter IV can negatively regulate BDNF expression. COMMENT We analyzed, by 3 independent sensitive quantitative methods, the DNA methylation degree at BDNF promoter IV and the global DNA methylation levels in the Wernicke area of the brain of 44 suicide subjects and 33 nonsuicide control subjects. The main conclusions of our work are (1) suicide subjects showed a statistically significant increase of DNA methylation at BDNF promoter IV and this higher methylation degree corresponded to a lower level of BDNF transcript IV; (2) such an increase in CpG methylation was gene specific since it was not accompanied by an increase of global DNA methylation; and (3) global DNA methylation levels in the Wernicke area varied among individuals but did not correlate with suicidal behavior and were not dependent on sex or age.
To our knowledge, the present work and the relative conclusions represent an absolute novelty for several aspects. In fact, the present study is novel in examining the possibility that BDNF hypermethylation could be associated with suicidality. This study was performed on samples of brain tissue obtained from the Wernicke area of suicide completers and control subjects who died of other causes. The Wernicke area was chosen for its function in understanding word meaning and semantic thinking and for its critical involvement with human language and associative and integrative functions. This fact is consistent with several findings of neurocognitive alterations in suicide attempters, such as an impairment in decision making 31, 32 and problem solving. 33 The Wernicke area and its connections with other brain structures represent a unique feature of the human brain, as suicidal behavior is peculiar to humans, and may influence many factors, including human social behavior. 34 Completed suicide cannot be considered a sudden and casual death but is the outcome of a process that involves a wide spectrum of thoughts, communications, and acts. It is consistent with this assumption that in suicidal behavior gene expression may be altered in a cortical area that has highly specialized integrative and associative functions. Moreover, postmortem studies reported an agerelated expression of BDNF in the temporal cortex, 35 suggesting that this neurotrophin is important in the early development of the temporal cortex. Suicidal behavior has been found to be associated with early traumatic experiences and this link could be based on early modifications in the expression of the BDNF gene.
The choice to analyze the methylation state of the BDNF gene derived from previous evidence that BDNF mRNA and protein levels are decreased in different postmortem brain areas (hippocampus and frontal cortex) 11, 12 and in the plasma 36 of suicide victims compared with nonsuicide controls. Human BDNF expression is controlled by a very complex regulatory region including 9 different transcription initiation sites driven by corresponding promoters. 14 We chose to analyze the DNA methylation of promoter IV because it has been previously established that the equivalent rat and murine promoters are strongly regulated during development and in adult neurons and that epigenetic mechanisms play a critical role in such transcriptional regulation. 6, [15] [16] [17] Of particular relevance are the observations that the epigenetic state of promoter IV may be also modulated in mouse and rat brain by several exogenous factors, such as membrane depolarization-induced calcium influx, 18, 19 chronic social defeat stress, and antidepressant administration. 6 These observations reinforce the growing hypothesis that complex epigenetic mechanisms, which may be modified by environment and may regulate gene activity without altering the DNA code, have long-lasting effects within mature neurons and are implicated in the regulation of human complex behavior, including psychiatric disorders. 20, 37, 38 Maya Vetencourt et al 39 showed that cortical administration of diazepam prevents the fluoxetine hydrochloride-mediated BDNF activation in the visual cortex, raising the interesting question of whether changes of BDNF expression or methylation state in suicide subjects may be influenced by drug consumption. However, in this study, we did not find any relationship between BDNF methylation or expression and diazepam or fluoxetine consumption in the study subjects. McGowan et al 40 demonstrated that in the brain of 11 suicide subjects with history of early childhood abuse, the ribosomal RNA gene was downregulated and hypermethylated compared with control subjects. Very interestingly, Ernst et al 41 found that trkB is hypermethylated in suicide completers in different brain areas.
Our study, relating the BDNF gene methylation state to sui-cidal behavior, strongly supports the conclusions of these studies and provides a possible mechanism responsible for the reduction of BDNF levels observed in the brain of suicide subjects. In the near future, it will be very interesting to extend the methylation analysis of the BDNF gene to other brain areas involved in suicidal behavior. Previous studies revealed that the methylation of specific CpG sites in the rat and mouse bdnf promoter IV may play a critical role in BDNF gene regulation. 15, 18 In particu- lar, CpG sites −128 and ϩ19 of the rat bdnf promoter IV may mediate, when methylated, the binding to MeCP2, which in turn is responsible for transcriptional repression. 18, 19 However, the role of DNA methylation in the control of BDNF expression has not been previously investigated in human tissues. In the present work, we show that CpG sites adjacent to the TSS of human BDNF transcript IV may play a role in the regulation of BDNF expression. In particular, statistical analysis showed that the methylation of CpG sites ϩ10 and ϩ25 is associated with suicidal behavior. Moreover, we showed that a higher methylation degree of these sites is associated with lower BDNF mRNA levels, suggestingthat,atleastinpart,DNAmethylationisinvolvedinBDNF transcriptional regulation in the human brain. Because we found much lower BDNF transcript IV mRNA levels in samples showing 20% to 30% methylation of 4 CpG sites in BDNF promoter IV compared with samples showing 3% to 5% methylation, we hypothesize that other mechanisms, including additional epigenetic mechanisms and/or lack of transcription factors, may contribute to such a strong repression. It will be very interesting to determine the relative role, in the regulation of BDNF expression, of CpG sites lying in the different BDNF gene promoters to study the possible association of the epigenetic state of other promoters with suicidal behavior. DNA methylation and other epigenetic factors could also provide some explanation for reportedconflictingdataontheassociationof BDNFgenepolymorphisms with suicidal behavior. 9, 10 In this study, we found a relatively low rate of suicide completers with a psychiatric disease. It cannot be excluded that in a few cases psychiatric conditions were present but were undiagnosed. However, the rate of diagnosed psychiatric diseases among suicide completers in our sample is comparable with the rate reported by other studies. 42 Moreover, the geographical region where the sample was collected has high suicide rates and it has been suggested that genetic component(s) might have an effect on increased suicide rates. 43 This genetic component possibly acts through personality features such as impulsive aggression. Overall, our study rein-forces the mounting hypothesis that DNA methylation is involved in psychiatric conditions and deviant human behaviors and represents one of the first demonstrations that alteration of gene-specific DNA methylation in the human brain is associated with suicidal behavior. We dedicate this study to our beloved friend and colleague Andrej Marusic, who largely contributed to the design and implementation of this research project. The absence of his brilliant mind consitutes a great loss for suicidology.
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